The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Animal models of biliary injury and altered bile acid metabolism
Open accessAbstract
In the last 25 years, a number of animal models, mainly rodents, have been generated with the goal to mimic cholestatic liver injuries and, thus, to provide in vivo tools to investigate the mechanisms of biliary repair and, eventually, to test the efficacy of innovative treatments. Despite fundamental limitations applying to these models, such as the distinct immune system and the different metabolism regulating liver homeostasis in rodents when compared to humans, multiple approaches, such as surgery (bile duct ligation), chemical-induced (3,5-diethoxycarbonyl-1,4-dihydrocollidine, DDC, α-naphthylisothiocyanate, ANIT), viral infections (Rhesus rotavirustype A, RRV-A), and genetic manipulation (Mdr2, Cftr, Pkd1, Pkd2, Prkcsh, Sec63, Pkhd1) have been developed. Overall, they have led to a range of liver phenotypes recapitulating the main features of biliary injury and altered bile acid metabolisms, such as ductular reaction, peribiliary inflammation and fibrosis, obstructive cholestasis and biliary dysgenesis. Although with a limited translability to the human setting, these mouse models have provided us with the ability to probe over time the fundamental mechanisms promoting cholestatic disease progression. Moreover, recent studies from genetically engineered mice have unveiled ‘core’ pathways that make the cholangiocyte a pivotal player in liver repair. In this review, we will highlight the main phenotypic features, the more interesting peculiarities and the different drawbacks of these mouse models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Mouse Models of Human Disease: An Evolutionary Perspective
Perlman, R. L. (2016) · Evolution, Medicine, and Public Health · doi:10.1093/emph/eow014 · Cited by 647
The mouse ascending: perspectives for human-disease models
Rosenthal, N., & Brown, S. (2007) · Nature Cell Biology · doi:10.1038/ncb437 · Cited by 442
Pathogenesis of cholestatic liver disease and therapeutic approaches
Hirschfield, G. M., Heathcote, E. J., & Gershwin, M. E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.09.004 · Cited by 287 · cited 2×
“impairment of bile formation and/or bile flow due to defective secretion by hepatocytes or cholangiocytes, or to mechanical obstruction of bile flow through intra- or extrahepatic bile ducts [1-3].”
Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease
Li, A., Davila, S., Furu, L., Qian, Q., Tian, X., Kamath, P. S., King, B. F., Torres, V. E., & Somlo, S. (2003) · The American Journal of Human Genetics · doi:10.1086/368295 · Cited by 193 · cited 1×
“The two known disease causative genes for ADPLD are PRKCSH and SEC63, which encode for non-cilial, ER-localized proteins involved in protein biogenesis and posttranslational modifications[92-94].”
Polycystin-1: A master regulator of intersecting cystic pathways
Fedeles, S. V., Gallagher, A.-R., & Somlo, S. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.01.004 · Cited by 130
Cited by
Animal models to study bile acid metabolism
Li, J., & Dawson, P. A. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.05.011 · Cited by 255
HMGB1 links chronic liver injury to progenitor responses and hepatocarcinogenesis
Hernandez, C., Huebener, P., Pradere, J.-P., Antoine, D. J., Friedman, R. A., & Schwabe, R. F. (2018) · Journal of Clinical Investigation · doi:10.1172/jci91786 · Cited by 110
Next-Generation Liver Medicine Using Organoid Models
Akbari, S., Arslan, N., Senturk, S., & Erdal, E. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00345 · Cited by 72
An update on animal models of liver fibrosis
Wu, S., Wang, X., Xing, W., Li, F., Liang, M., Li, K., He, Y., & Wang, J. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1160053 · Cited by 71
Multi-zonal liver organoids from human pluripotent stem cells
Reza, H. A., Santangelo, C., Iwasawa, K., Reza, A. A., Sekiya, S., Glaser, K., Bondoc, A., Merola, J., & Takebe, T. (2025) · Nature · doi:10.1038/s41586-025-08850-1 · Cited by 71
A spatiotemporal atlas of cholestatic injury and repair in mice
Wu, B., Shentu, X., Nan, H., Guo, P., Hao, S., Xu, J., Shangguan, S., Cui, L., Cen, J., Deng, Q., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01687-w · Cited by 65
Roehlen, N., Saviano, A., El Saghire, H., Crouchet, E., Nehme, Z., Del Zompo, F., Jühling, F., Oudot, M. A., Durand, S. C., Duong, F. H. T., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abj4221 · Cited by 54
Liver macrophages: development, dynamics, and functions
Nusse, Y., & Kubes, P. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01298-3 · Cited by 50
Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma
Paillet, J., Plantureux, C., Lévesque, S., Le Naour, J., Stoll, G., Sauvat, A., Caudana, P., Tosello Boari, J., Bloy, N., Lachkar, S., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20200853 · Cited by 41
Dissecting the single-cell transcriptome underlying chronic liver injury
Wang, J., Hu, W., Shen, Z., Liu, T., Dai, W., Shen, B., Li, X., Wu, J., Lu, L., Li, S., et al. (2021) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2021.11.008 · Cited by 26
Metadata
- Authors
- Mariotti, V., Strazzabosco, M., Fabris, L., & Calvisi, D. F.
- Venue
- Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 1864
- Issue
- 4
- Pages
- 1254-1261
- ISSN
- 0925-4439 (ISSN-L)
- OpenAlex
- W2734346062
- Cited by
- 176
- References
- 6
- FWCI
- 6.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.